Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?

Breast cancers (BC) associated with germline mutations of BRCA1/2 represent 3–5% of cases. BRCA1/2-associated BC have biological features leading to genomic instability and potential sensitivity to DNA damaging agents, including poly(ADP-ribose) polymerase (PARP) and platinum agents. In this review,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolas, Emanuel, Bertucci, François, Sabatier, Renaud, Gonçalves, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316565/
https://www.ncbi.nlm.nih.gov/pubmed/30544963
http://dx.doi.org/10.3390/cancers10120506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316565/
https://www.ncbi.nlm.nih.gov/pubmed/30544963
http://dx.doi.org/10.3390/cancers10120506

Ejemplares similares